



FORMATEUR
D^R VINCENT AUFRÉT
MÉDECIN CARDIOLOGUE

Le Dr Vincent Auffret est cardiologue et praticien hospitalier universitaire dans le service de cardiologie et maladies vasculaires du CHU de Rennes. Il y est responsable médical de l'Unité fonctionnelle d'hospitalisation de semaine.

Après un séjour à l'Institut Universitaire de Cardiologie et Pneumologie de Québec, il est depuis 2019 titulaire d'une thèse de science portant sur l' « Aide à la décision dans le remplacement valvulaire aortique percutané ».

Ses travaux universitaires portent sur le traitement percutané des coronaropathies et des valvulopathies. Il a contribué à plus de 70 articles scientifiques référencés dans son domaine de spécialité.

ARTICLES SCIENTIFIQUES

- Auffret V et al.**
Determinants and impact of heart failure readmission following transcatheter aortic valve replacement.
Circ Cardiovasc Interv. 2020; 13(7): e008959.
- Auffret V et al.**
Conduction disturbances following transcatheter aortic valve implantation: increasing the 'pace' towards prospective evidence.
Eur Heart J. 2020; 20: ehz957.
- Auffret V et al.**
Pharmacoinvasive strategy versus primary percutaneous coronary intervention for ST-Segment elevation myocardial infarction in patients ≥70 years of age.
Am J Cardiol. 2020; 125(1):1-10.
- Leurent G, Auffret V et al.**
Is there still a role for the intra-aortic balloon pump in the management of cardiogenic shock following acute coronary syndrome?
Arch Cardiovasc Dis. 2019; 112(12):792-798.
- Beve M, Auffret V et al.**
Comparison of the transarterial and transthoracic approaches in nontransfemoral transcatheter aortic valve implantation.
Am J Cardiol. 2019; 123(9):1501-1509.
- Auffret V et al.**
Idiopathic/iatrogenic left bundle branch block-induced reversible left ventricle dysfunction: JACC state-of-the-art review.
J Am Coll Cardiol. 2018; 72(24): 3177-3188.
- Benamer H, Auffret V et al.**
Position paper of French Interventional Group (GACI) for TAVI in France in 2018.
Ann Cardiol Angeiol (Paris). 2018; 67(6):455-465.
- Helleu B, Auffret V et al.**
Current indications for the intra-aortic balloon pump: The CP-GARO registry.
Arch Cardiovasc Dis. 2018; 111(12):739-748.
- Auffret V et al.**
ORBI and RICO Working Groups. Predicting the development of in-hospital cardiogenic shock in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: the ORBI risk score.
Eur Heart J. 2018; 39(22):2090-2102.
- Vy P, Auffret V et al.**
Patient-specific simulation of guidewire deformation during transcatheter aortic valve implantation.
Int J Numer Method Biomed Eng. 2018; 34(6):e2974.
- Pimor A, Auffret V et al.**
Immediate complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease treated by primary percutaneous coronary intervention: Insights from the ORBI registry.
Arch Cardiovasc Dis. 2018; 111(11):656-665.
- Auffret V et al.**
Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives.
Circulation. 2017;136(11):1049-1069.
- Auffret V et al.**
Transcatheter Aortic Valve Implantation Versus surgical aortic valve replacement in lower-surgical-risk patients with chronic obstructive pulmonary disease.
Am J Cardiol. 2017;120(10):1863-1868.
- Auffret V et al.**
Clinical impact of baseline right bundle branch block in patients undergoing transcatheter aortic valve replacement.
JACC Cardiovasc Interv. 2017; 10(15):1564-1574.
- Puri R, Auffret V et al.**
Bioprosthetic valve thrombosis.
J Am Coll Cardiol. 2017; 69(17):2193-2211.
- Auffret V et al.**
Feasibility, safety, and efficacy of transcatheter aortic valve replacement without balloon predilation: A systematic review and meta-analysis.
Catheter Cardiovasc Interv. 2017; 90(5):839-850.

Liste complète disponible sur :
<https://pubmed.ncbi.nlm.nih.gov/?term=auffret+v&sort=date&size=100>

ARTICLES SCIENTIFIQUES

Auffret V et al.

The challenging realm of neurocognitive evaluation following transcatheter aortic valve implantation.
Arch Cardiovasc Dis. 2017; 110(4):203-205.

Auffret V et al.

Prevalence and impact of prosthesis-patient mismatch following surgical aortic valve replacement for pure aortic regurgitation.
J Heart Valve Dis. 2016; 25(5):543-551.

Auffret V et al.

Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
Arch Cardiovasc Dis. 2016; 109(12):696-707.

Auffret V et al.

Serial changes in cognitive function following transcatheter aortic valve replacement.
J Am Coll Cardiol. 2016; 68(20):2129-2141.

Auffret V et al.

Predictors of early cerebrovascular events in patients with aortic stenosis undergoing transcatheter aortic valve replacement.
J Am Coll Cardiol. 2016; 68(7):673-84.

Auffret V et al.

Incidence, timing, predictors and impact of acute heart failure complicating ST-segment elevation

myocardial infarction in patients treated by primary percutaneous coronary intervention.
Int J Cardiol. 2016;221:433-42.

Auffret V et al.

High-degree atrioventricular block complicating ST segment elevation myocardial infarction in the contemporary era.
Heart. 2016; 102(1):40-9.

Auffret V et al.

Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: Insights from the French «real-world» prospective GARO Registry.
Int J Cardiol. 2016; 203:690-6.

Auffret V et al.

Efficacy of pre-hospital use of glycoprotein IIb/IIIa inhibitors in ST-segment elevation myocardial infarction before mechanical reperfusion in a rapid-transfer network (from the acute myocardial infarction registry of brittany).
Am J Cardiol. 2014; 114(2):214-23.

Auffret V et al.

Predictors of 6-month poor clinical outcomes after transcatheter aortic valve implantation.
Arch Cardiovasc Dis. 2014; 107(1):10-20.

Liste complète disponible sur :

<https://pubmed.ncbi.nlm.nih.gov/?term=auffret+v&sort=date&size=100>